垂体催乳素瘤的临床特点及诊治要点更新--基于《2022版ICCE/AME垂体催乳素瘤临床实践共识》解读  

Interpretation of the 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma:Update on Clinical Characteristics and Points of Diagnosis and Treatment of Pituitary Prolactinoma

作　　者：谭惠文[1,2] 李丹婷 余叶蓉[1,2] TAN Huiwen;LI Danting;YU Yerong(Department of Endocrinology and Metabolism,West China Hospital,Sichuan University,Chengdu 610041,China;Pituitary Tumor and Related Diseases Diagnosis and Treatment Center,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院内分泌代谢科,四川省成都市610041 [2]四川大学华西医院垂体瘤及相关疾病诊疗中心,四川省成都市610041

出　　处：《中国全科医学》2024年第6期650-655,共6页Chinese General Practice

基　　金：四川省卫生健康委员会项目(20PJ046);四川省科技厅干部保健课题基金(GBKT22014);四川大学华西医院学科卓越发展1·3·5工程临床研究孵化项目(2020HXFH034)。

摘　　要：垂体催乳素瘤是一种由垂体催乳素细胞瘤过量合成和分泌催乳素引起的神经内分泌疾病,垂体催乳素瘤的规范化诊疗对于恢复并维持患者的正常垂体功能并提高其生活质量具有重要意义。2022年1月,《欧洲内分泌杂志》发布了国际临床内分泌学分会(ICCE)与意大利临床内分泌学家协会(AME)关于垂体催乳素瘤的临床实践最新共识申明——《2022版ICCE/AME垂体催乳素瘤临床实践共识》(简称2022版ICCE/AME新共识)。2022版ICCE/AME新共识立足最新循证医学证据,对于垂体催乳素瘤的临床诊治问题进行系统性阐述、分析和建议。本文围绕2022版ICCE/AME新共识关于垂体催乳素瘤的诊断、治疗、特殊人群、多巴胺激动剂抵抗及侵袭性疾病等诊治要点更新进行解读,希望有助于全科医生及内分泌专科医生对于垂体催乳素瘤的认识,为其临床实践的规范化诊疗提供参考。Pituitary prolactinoma is a neuroendocrine disease caused by excessive pituitary prolactin-cell adenoma synthesis and prolactin secretion.The standardized diagnosis and treatment of pituitary prolactinoma in of great significance for recovering and maintaining pituitary function and improving life quality of the patients.In January 2022,the International Chapter of Clinical Endocrinology(ICCE)and the Italian Association of Clinical Endocrinologists(AME)published a position statement on pituitary prolactinoma in the European Journal of Endocrinology:2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma(abbreviated as 2022 ICCE/AME position statement).Based on the latest medical evidence,2022 ICCE/AME position statement conducts a systematic review,analysis and recommendations on the clinical diagnosis and treatment of pituitary prolactinoma.This article provides an update on the diagnosis and treatment of pituitary prolactinoma,special populations,dopamine agonist resistance,and invasive prolactinoma in the 2022 ICCE/AME position statement,which is hoped to be helpful to the awareness of pituitary prolactinoma among general practitioners and endocrinologists,and provide a reference for the clinical practice of standardized diagnosis and treatment.

关 键 词：催乳素瘤 垂体肿瘤 高催乳素血症 指南 催乳素 多巴胺激动剂 药物治疗 

分 类 号：R736.4[医药卫生—肿瘤]